Ren Y - Search Results

1

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.

Zhang C, Denti P, Decloedt EH, Ren Y, Karlsson MO, McIlleron H. Zhang C, et al. Among authors: ren y. Br J Clin Pharmacol. 2013 Nov;76(5):741-51. doi: 10.1111/bcp.12101. Br J Clin Pharmacol. 2013. PMID: 23432610 Free PMC article. Clinical Trial.

2

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):566-9. doi: 10.1097/QAI.0b013e3181642257. J Acquir Immune Defic Syndr. 2008. PMID: 18197120

3

Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US. Elsherbiny D, et al. Among authors: ren y. Eur J Clin Pharmacol. 2010 Oct;66(10):1017-23. doi: 10.1007/s00228-010-0847-9. Epub 2010 Jun 16. Eur J Clin Pharmacol. 2010. PMID: 20552180 Free article.

4

Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.

McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, Cotton M, Eley B, Meyers T, Smith PJ, Merry C, Maartens G. McIlleron H, et al. Among authors: ren y. Antivir Ther. 2011;16(3):417-21. doi: 10.3851/IMP1757. Antivir Ther. 2011. PMID: 21555825

5

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.

Zhang C, McIlleron H, Ren Y, van der Walt JS, Karlsson MO, Simonsson US, Denti P. Zhang C, et al. Among authors: ren y. Antivir Ther. 2012;17(1):25-33. doi: 10.3851/IMP1915. Antivir Ther. 2012. PMID: 22267466 Free PMC article.

6

Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.

Zhang C, Denti P, van der Walt JS, Ren Y, Smith P, Karlsson MO, McIlleron H. Zhang C, et al. Among authors: ren y. Ther Drug Monit. 2012 Aug;34(4):481-4. doi: 10.1097/FTD.0b013e31825c6067. Ther Drug Monit. 2012. PMID: 22722777

7

High prevalence of subtherapeutic plasma concentrations of efavirenz in children.

Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):133-6. doi: 10.1097/QAI.0b013e31805c9d52. J Acquir Immune Defic Syndr. 2007. PMID: 17417100 Clinical Trial.

8

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3. J Acquir Immune Defic Syndr. 2009. PMID: 19223781 Clinical Trial.

9

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.

McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. McIlleron HM, et al. Among authors: ren y. AIDS. 2013 Jul 31;27(12):1933-40. doi: 10.1097/qad.0b013e328360dbb4. AIDS. 2013. PMID: 24180002 Free PMC article.

10

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.

Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. Swart M, et al. Among authors: ren y. Pharmacogenet Genomics. 2013 Aug;23(8):415-27. doi: 10.1097/FPC.0b013e328363176f. Pharmacogenet Genomics. 2013. PMID: 23778320

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,348 results

Search Page

Filters